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Abstract The uptake of free and esterified cholesterol at the 
brush border membrane is protein-mediated. Here we show that 
this sterol uptake is effectively inhibited by exchangeable serum 
apolipoproteins. Binding of the apolipoprotein to the brush 
border membrane mediates the inhibitory effect. Evidence is 
presented to show that the structural motif responsible for the 
inhibition is the amphipathic a-helix. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
We have shown that the absorption of free and esterified 
cholesterol in the small intestine is protein-mediated [1-3]. 
Using small-intestinal brush border membrane vesicles 
(BBMV), intact enterocytes and Caco-2 cells, ample experi-
mental proof is now available for a transporter in the brush 
border membrane (BBM) [4,5]. This is at variance with the 
widely accepted view documented in review articles and text 
books that dietary lipids diffuse passively along a concentra-
tion gradient from the lumen of the small intestine to the 
cytosol of enterocytes. Here we show that serum apolipopro-
teins, their lipidated forms and amphipathic oc-helical peptides 
inhibit sterol uptake by BBMV. This inhibition will have im-
portant implications for the development of compounds and 
methods to reduce the uptake of dietary fats, particularly 
cholesterol. 
2. Materials and methods 
2.1. Materials 
Egg phosphatidylcholine (PC) and dimyristoyl PC were purchased 
from Lipid Products (Nutfield, Surrey, UK), sodium dextran sulfate, 
Phenyl Sepharose 6 Fast Flow, Q-Sepharose Fast-Flow, Sephadex G-
50, PBE 94 and Polybuffer 74 for chromatofocusing from Pharmacia 
(Diibendorf, Switzerland), cholesterol (purity > 99%) from Fluka, 
cholesteryl oleate (purity > 98%) from Sigma (Buchs, Switzerland), 
bicinchoninic acid protein assay reagent and monoclonal anti-human 
apolipoprotein (apo) A-I antibodies from Pierce (Lausanne, Switzer-
land). [4-,4C]cholesterol (~50 Ci/mol) and [la,2oc(n)-3H]cholesteryl 
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oleyl ether (37 Ci/mmol) were obtained from Amersham (UK). Sheep 
serum was obtained from the Basel Institute of Immunology (Basel, 
Switzerland) and stored at —80°C prior to use. 
2.2. Preparation of donor and acceptor particles 
BBMV as the acceptor membrane were routinely prepared from 
rabbit duodenum and jejunum according to [6]. As a quality control 
some physicochemical properties of the BBMV were determined rou-
tinely as described in [4] and [6]. Furthermore, the stability and in-
tegrity of the BBMV were checked by determining the specific activity 
of marker enzymes and the Na+-dependent glucose uptake [6]. Small 
unilamellar vesicles (SUV) of egg PC containing 1 mol% cholesterol 
or 1 mol% cholesteryl oleate and a trace amount of [4-14C]cholesterol 
or [la,2a(n)-3H]cholesteryl oleyl ether, respectively, were used as do-
nor particles and made according to [7]. Both donor and acceptor 
particles were dispersed in Tris-NaCl buffer (0.05 M Tris, pH 7.4, 
0.15 M NaCl, 0.02% NaN3). 
2.3. Isolation and purification of inhibitors of sterol uptake 
We observed that sheep serum inhibits the protein-catalysed ab-
sorption of free and esterified cholesterol by BBMV. This striking 
result prompted the isolation and purification of the inhibitory factor. 
Lipoprotein-depleted sheep serum produced by sequential ultracentri-
fugation according to [8] was inactive; all the inhibitory activity was 
found in the lipoprotein fraction. When sheep serum was fractionated 
with dextran sulfate and Mn2+ according to [9], most of the activity 
was recovered in the HDL fraction. This fraction was further purified 
by hydrophobic interaction chromatography using a Phenyl Sephar-
ose 6 Fast Flow column (6.5X2.8 cm) equilibrated with 0.05 M Tris-
HC1, pH 7.4, 2 M NaCl. Nearly all of the inhibitory activity applied 
to the column was bound. After washing out the flow-through pro-
teins, bound proteins were eluted with 0.15 M NaCl (fraction 1), with 
H 2 0 (fraction 2) and 15% ethanol (fraction 3, Table 1). The specific 
inhibitory activity of fraction 2 eluted with water was increased by a 
factor of 15 relative to the HDL fraction. Fraction 2 was further 
purified by chromatofocusing on polybuffer exchanger 94. The activ-
ity was eluted with a pH gradient from 7 to 3.8 [10] yielding a single 
symmetric peak centered at pH 5.4 (Fig. 1). The specific activity of 
this fraction was increased by a factor of 65 relative to sheep serum. 
For amino acid sequencing the purified protein was subjected to SDS-
15% PAGE, transferred to a PVDF membrane, and sequenced on an 
Applied Biosystem 477A protein sequencer. 
Pure human apo A-l and apo A-1I were prepared from human 
high-density lipoprotein (HDL) by delipidation [11] and ion exchange 
chromatography on Q-Sepharose [12]. The purity of apo A-I and 
apo A-II was checked by SDS-PAGE with 8-25% gradient gels using 
a Phast Electrophoresis system (Pharmacia). Both proteins gave single 
bands on overloaded gels. Prior to use, the proteins were solubilized 
in 3 M guanidine HC1 and dialyzed against the Tris-NaCl buffer. 
Human apo A-IV was a gift of Dr. P. Tso of LSU Medical Center 
and pure by SDS-PAGE. Human HDL3 (density d= 1.125-1.21 g/ml) 
was isolated from fresh plasma of normallipidemic donors by sequen-
tial centrifugation [8]. The HDL3 preparation was pure by electro-
phoresis in 0.5% agarose gels. A reconstituted discoidal HDL particle 
was obtained by interacting lipid-free apo A-I with an unsonicated 
dimyristoyl PC dispersion at 24°C according to [13]. 
The peptides Ac-18A-NH2 (CH3CO-DWLKAFYDKVAEKL-
KEAF-NH2) and Ac-18S-NH2(CH3CO-DWLAKDYFKKALVEE-
FAK-NH2) [14-16] were synthesized by solid-phase synthesis with 
the N-terminus being acetylated and the C-terminus amidated and 
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supplied by Anawa Biomedical Services and Products (Zurich, Swit-
zerland). The purities were better than 95% as assessed by HPLC. The 
molecular weights of the two peptides determined by mass spectrom-
etry were consistent with the calculated values. 
2.4. Lipid uptake by BBMV 
The kinetics of sterol uptake by BBMV were measured as described 
before [\-Q (see legend of Fig. 3). The inhibitor concentration IC50 
required to produce 50% inhibition was determined as follows: the 
rate of sterol uptake by BBMV was determined by incubating donor 
(0.05 mg total lipid/ml) and acceptor (BBMV at 2 mg protein/ml) for 
20 min at 23°C with and without inhibitor. Sterol uptake by BBMV in 
the absence of inhibitor was taken as 100%, and the reduced uptake 
activity measured in the presence of inhibitor was expressed as percent 
inhibition. This yielded dose-response curves relating percent inhibi-
tion to the total inhibitor concentration (cf., Fig. 4). The data points 
of these dose-response curves were fitted by a modified Hill equation 
[17]: 
y=\/[\ + {lCm/xT] 
where y is percent of inhibition, x the total inhibitor concentration 
and n the Hill coefficient. The programs MacCurveFit (Kevin Raner 
Software, Victoria, Australia) and Excel (Microsoft) were used on a 
Macintosh computer. 
2.5. Analytical methods 
The molecular mass of the peptides and proteins was determined by 
matrix-assisted laser desorption ionization mass spectrometry using 
time-of-flight mass analysis (Voyager Elite mass spectrometer from 
PerSeptive Biosystem). Phospholipid concentrations were determined 
according to [18] and protein concentrations by the bicinchoninic acid 
method [19]. 
3. Results 
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Fig. 1. Chromatofocusing of the partially purified inhibitor on poly-
buifer exchanger 94. Protein (35 mg) of fraction 2 (Table 1) was ap-
plied to a 20 ml polybuffer exchanger column (25.5X1 cm) equili-
brated with 0.025 M imidazole-HCL buffer, pH 7.3. The inhibitory 
activity bound to the column was eluted at 0.5 ml/min with a linear 
pH gradient from 7 to 3.8 generated with polybuffer 74. Fractions 
of 8 ml were collected and analysed for protein and inhibitory activ-
ity. Solid line: protein content; dashed line: pH gradient; dotted 
line and squares: inhibitory activity in arbitrary units (au). 
3.1. Isolation, purification and identification of the inhibitor 
We discovered serendipitously that sheep serum inhibited 
effectively sterol uptake by BBMV. Consequently, the inhibit-
ing factor was isolated from sheep serum and purified to ho-
mogeneity. The main peak obtained by chromatofocusing at 
pH 5.4 (Fig. 1) gave a single band on SDS-15% PAGE using 
silver staining with an apparent molecular mass of 28 kDa 
(Fig. 2A). The sequence of the first 29 NH2-terminal amino 
acids (Fig. 2B) was highly homologous to human (69%), rab-
bit (73%), rat (83%) and bovine apo A-I (90%). The molecular 
mass of the purified inhibitor determined by mass spectrom-
etry was 27.57 kDa. The isoelectric point of the protein de-
termined by chromatofocusing was 5.40 (Fig. 1). These values 
are in excellent agreement with published data on human and 
rabbit apo A-I [20]. Immunoblot analysis of the purified in-
hibitor using monoclonal antibodies against human apo A-I 
revealed a clear-cut immunological cross-reactivity between 
the purified inhibitor and human apo A-I. Lipid analysis in-
dicated that the purified inhibitor contained phospholipid 
(0.45 mg phospholipid/mg protein) and cholesterol (0.26 mg 
cholesterol/mg protein). We conclude that the inhibitor iso-
Table 1 
Hydrophobic chromatography of HDL on Phenyl Sepharose 
Fractions Elution of inhibitory activity 
(au) (%) (au/mg protein) 
Flow-through 
Fraction 1 
Fraction 2 
Fraction 3 
2.8 XlO4 
3.1 X104 
9.6 X105 
1.6X105 
2 
3 
81 
14 
80 
430 
2.7 XlO4 
4.1 XlO4 
The HDL fraction applied to the column contained 0.6 g protein and 
an activity of 1.1 X 106 arbitrary units (au). 
lated from sheep serum is a partially delipidated HDL, (there-
after referred to as sheep HDL) [21]. 
3.2. Sterol uptake by small-intestinal BBMV in the absence and 
presence of human apo A-I 
The kinetics of cholesteryl oleate uptake by BBMV in the 
absence and presence of human apo A-I are shown in Fig. 3. 
The kinetic curve in the absence of apo A-I was adequately 
fitted by the sum of two exponential functions while that in 
the presence of apo A-I was fitted best by a single exponential 
decay (see dotted lines, Fig. 3). Pseudo-first-order rate con-
stants k (half-times ti/2) derived from curve fitting gave the 
following values: in the absence of apo A-I the values were 
h= 0.46±0.04 min"1 (f1/2 = 1.5 min) and k2 = 0.66±0.1 h"
1 
{h/2 = 1-1 h) for the initial fast phase and the second slow 
phase, respectively. In the presence of apo A-I the single ex-
ponential decay was characterized by k\= 0.36±0.06 h _ 1 
(?!/2 = 1.93 h). In the absence of apo A-I the final equilibrium 
Xoo obtained from curve fitting was 3%> entirely consistent with 
the experimental value (Fig. 3). So the effect of the inhibitor is 
to abolish the initial fast phase of sterol uptake and to shift 
the final equilibrium x„ from 3 to 37% (Fig. 3). 
Cholesteryl oleate was used as a representative sterol and 
cholesteryl oleyl ether as its nonhydrolyzable analogue. Ester 
and ether compounds behaved identically with respect to the 
uptake kinetics [2]. As shown before [2], the kinetics of chol-
esterol uptake were similar to those of cholesteryl oleate, and 
this was also true for the kinetics of sterol uptake in the 
presence of apo A-I. With cholesterol there was a small but 
still measurable contribution to the uptake from passive dif-
fusion. With the more hydrophobic cholesteryl oleate 
this contribution was negligible and in this case no cor-
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Fig. 2. A: SDS-15% PAGE pattern of the inhibitory activity isolated and purified from sheep serum. SDS-PAGE was carried out using the 
Mini-Protean II dual slab cell from Bio-Rad according to the Bio-Rad instruction manual. Proteins were made visible by silver staining. Bio-
Rad low-range protein standards were used and the positions of apparent molecular masses in kDa are marked. B: The sequence of the first 
29 NH2-terminal amino acids of the inhibitory protein isolated and purified from sheep serum is compared to the NH2-terminal sequences of 
human and bovine apo A-I. Conservative replacements are indicated by dashed lines. 
rection had to be made. For this reason the discussion of the 
data for cholesteryl oleate presented in Fig. 3 is straight-for-
ward. 
The inhibiting effect of apo A-I is presented as a dose-re-
sponse curve and compared to the effect of other inhibitors in 
Fig. 4. The dose-response curves for the inhibition of free and 
esterified cholesterol uptake measured for apo A-I, apo A-II, 
HDL3 and Ac-18A-NH2 were identical within experimental 
error (cf, IC50 values, Table 2). The data in Fig. 4 demon-
strate that sterol uptake by BBMV is effectively and com-
pletely inhibited by apo A-I concentrations of ~100 |o.g/ml. 
Other serum apolipoproteins and the synthetic peptide Ac-
I8A-NH2 were also effective though to a different extent (Ta-
ble 2). The lipidated forms of apo A-I such as sheep HDL, 
human HDL3 and the discoidal lipoprotein particles reconsti-
tuted from human apo A-I and dimyristoyl PC also effectively 
inhibited sterol uptake. 
Control experiments were carried out to show that apo A-I 
as a detergent-like molecule neither changes the average size 
of the donor vesicles nor does it solubilize BBMV at concen-
trations used in this study. 
4. Discussion 
4.1. Mechanism of inhibition 
The mechanism(s) by which lipid molecules cross the BBM 
remains to be elucidated, partly because of the unavailability 
of specific inhibitors. Here, we report that sterol uptake by 
BBMV is effectively and completely inhibited by apo A-I and 
the lipidated forms of apo A-I such as HDL and discoidal 
lipoprotein particles reconstituted from apo A-I and dimyris-
toyl PC. In principle, apo A-I could inhibit sterol uptake by 
interacting with either the donor SUV or the acceptor BBMV. 
With regard to the donor, apo A-I could change the structure 
of the SUV and prevent sterol transfer. This is clearly not the 
case. We studied the interaction of apo A-I with egg PC SUV 
using gel filtration on Sepharose CL-4B. The binding param-
eters derived were in good agreement with published values 
[22]. Under the conditions of lipid uptake (Fig. 3) only about 
2% of apo A-I was bound to the SUV, and the size distribu-
tion of egg PC SUV remained unchanged as determined by gel 
filtration on Sepharose CL-4B. Furthermore, apo A-I-con-
taining SUV of egg PC still give passive cholesterol transfer 
[23]. 
With regard to the acceptor, since apo A-I is an amphi-
pathic protein, and thus a detergent, it could solubilize 
BBMV. This is not the case. At apo A-I concentrations 
used in our lipid uptake measurements (Fig. 3) the average 
size and size distribution of the BBMV remained unaltered. 
Clear-cut evidence to this effect was obtained by light scatter-
ing and freeze-fracture electron microscopy. The structural 
integrity of these BBMV was maintained despite the fact 
that apo A-I does bind to BBMV. Binding could be demon-
strated unambiguously by using 14C-labeled apo A-I. The in-
hibition produced by apo A-I (Fig. 3) was largely reversible. 
Thorough washing of BBMV, which had lost their protein-
mediated sterol uptake ability due to exposure to apo A-I, 
restored the protein-mediated sterol uptake to about 80-
90%. Apo A-I binds to the BBMV and this binding leads to 
inhibition. 
Table 2 
IC50 values for inhibition of cholesterol and cholesteryl oleate uptake by small-intestinal BBMV 
Protein, peptide IQo* 
Cholesteryl oleate 
(ug/ml) OiM) 
Cholesterol 
(Ug/ml) (MM) 
Human apo A-I 
Human apo A-II 
Human apo A-IV 
Human apo A-I in discoidal HDL particles 
Human HDL3 
Sheep HDL 
Ac-18A-NH2 
11 ± 1 
8±2 
32 ±4 
25 ±5 
29±2 
8±2 
33±2 
0.4 ±0.04 
0.5 ±0.1 
0.7 ±0.1 
0.9 ±0.2 
1.0 ± 0.1 
0.3 ±0.1 
15 ±1 
10±1 
10±2 
28 ±1 
30±2 
0.35 ±0.04 
0.6 ±0.1 
1.0 ±0.05 
14 ±1 
"Values are the averages of three separate experiments in duplicate. In the cases of lipoprotein particles concentrations are expressed in terms of 
apo A-I using a molecular mass of 28 000. 
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4.2. Structural requirement of the inhibitor 
The data summarized in Table 2 indicate that the inhibitory 
effect is not specific for apo A-I because human apo A-II, and 
apo A-IV also inhibited sterol uptake. The inhibitory effect 
appears to be characteristic of the class of exchangeable apo-
lipoproteins. Since these apolipoproteins all have different 
amino acid sequences, the inhibition cannot be due to a spe-
cific amino acid sequence occurring in one of these apolipo-
proteins. A structural motif that is common to this class of 
proteins is the amphipathic oc-helix [15,24]. The hypothesis 
that the amphipathic oc-helix is the structural principle under-
lying the inhibition is readily subjected to test. To this end the 
amphipathic peptide Ac-18A-NH2 (CH3CO-DWLKAFYDK-
VAEKLKEAF-NH2) was designed to have minimal homol-
ogy to naturally occurring amphipathic oc-helices [14]. It pos-
sesses the characteristics of class A amphipathic a-helices as 
present in apo A-I: the positively charged Lys are present at 
the polar-nonpolar interface, the negatively charged Asp and 
Glu are present at the centre of the polar face and the polar 
and nonpolar faces have approximately equal surface areas 
[14,15,22]. The addition of the acetyl group at the NH2-termi-
nus and amidation at the C-terminus were reported to pro-
duce a large increase in the helicity of the peptide both in 
solution and when bound to lipids [15]. Thus Ac-18A-NH2 
is an idealized amphipathic, a-helical peptide that was shown 
to mimic some properties of apo A-I [14]. As evident from 
Fig. 4 and Table 2, Ac-18A-NH2 is an effective inhibitor of 
sterol uptake at the BBM. That the amphipathic oc-helix is the 
structural principle underlying the inhibition is supported by 
the observation that the peptide Ac-18S-NH2 (CH3CO-
DWLAKDYFKKALVEEFAK-NH2) was inactive. This pep-
tide is scrambled Ac-18A-NH2: it has the same amino acid 
composition as 18A, but the amino acid sequence is random-
ized to eliminate the amphipathic character of the helical pep-
tide [16]. 
The finding reported here may be physiologically relevant. 
Small-intestinal epithelial cells are short-lived (48-72 h) and 
eventually shed into the lumen of the small intestine. Since 
these cells are one of the major sites of apo A-I biosynthesis, 
it is feasible that apo A-I released from shed cells inhibits 
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Fig. 3. The kinetics of cholesteryl oleate uptake by BBMV. Egg PC 
SUV as the donor containing 1 mol% cholesteryl oleate trace-la-
beled with [3H]cholesteryl oleyl ether (0.05 mg total lipid/ml) were 
incubated with BBMV (5 mg protein/ml; 3 mg total lipid/ml) at 
23°C in the absence (■) and presence of human apo A-I (•) at 45 
ug protein/ml. Both donor and acceptor were dispersed in Tris-
NaCl buffer. 
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Fig. 4. Inhibition of cholesterol and cholesteryl oleate uptake by 
BBMV expressed as percent as a function of increasing amounts of 
different inhibitors. The sterol uptake activity of BBMV measured 
in the absence of inhibitor was taken as 100% and the loss in this 
activity observed in the presence of inhibitor is expressed as percent 
inhibition. Human apo A-I (■); human HDL3 (•) and peptide Ac-
18A-NH2 (□). The standard deviation of three different measure-
ments in duplicate was <5%; therefore error bars were omitted. 
The solid and dotted lines were obtained by curve fitting using a 
modified Hill equation [17]. 
cholesterol uptake at the BBM. To answer the question of 
the physiological relevance would require the knowledge of 
the effective apo A-I concentration in the small-intestinal lu-
men. 
Elucidation of the mechanism of inhibition of sterol uptake 
at a molecular level has to await the systematic study of 
structure-activity relations using different apolipoproteins as 
well as model peptides. The inhibition of sterol uptake at the 
BBM holds great potential for controlling cholesterol absorp-
tion in vivo. Our discovery raises the prospect of future devel-
opment of drugs targeted against the sterol transporter in the 
BBM. Such agents would have wide applications in the con-
trol of atherosclerosis. 
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